OPRX
OptimizeRx Corporation
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
7.71
▼ 0.25 (3.14%)
MARKET · —
Price
Open
8.05
Prev close
7.96
Day high
8.12
Day low
7.59
Volume
130.74K
Market cap
$145.23M
P/E (TTM)
30.84
52W range
4.54 – 22.25
Trailing performance
Returnvs SPY
1W
-11.58%
-10.2%
1M
+24.15%
+20.4%
3M
+56.07%
+53.0%
6M
-5.98%
-17.0%
YTD
-37.11%
-49.4%
1Y
-50.23%
-70.2%
3Y
-13.66%
-87.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$145.23M
Enterprise value$140.61M
Revenue (TTM)$98.65M
Gross profit$72.24M
EBITDA$15.55M
Net income$4.60M
EPS (TTM)$0.25
Free cash flow$15.76M
Total cash$24.10M
Total debt$19.48M
Book value / share$6.91
Shares outstanding18.84M
Float14.50M
Short % of float7.59%
Dividend yield—
Beta (5Y)1.05
Valuation & profitability ratios
Trailing P/E30.84
Forward P/E7.29
PEG ratio1.61
Price / sales—
Price / book1.12
EV / revenue1.43
EV / EBITDA9.04
Gross margin73.22%
Operating margin-0.43%
Profit margin4.66%
Return on equity3.67%
Return on assets4.22%
Debt / equity14.86
Current ratio5.58
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $109.43M | $92.13M | $71.52M | $62.45M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $5.13M | -$20.11M | -$17.57M | -$11.44M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $5.13M | -$20.11M | -$17.57M | -$11.44M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.11 | 0.16 | +42.9% |
| Mar 2026 | 0.00 | — | — |
| Dec 2025 | 0.22 | 0.51 | +127.4% |
| Sep 2025 | 0.04 | 0.20 | +438.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.17 | 4 | $21.62M | -17.1% |
| Next quarter | 0.41 | 4 | $34.64M | +7.4% |
| Current year | 0.89 | 4 | $96.62M | -11.7% |
| Next year | 1.06 | 4 | $107.64M | +11.4% |
Analyst targets & ownership
Mean target$12.40
High target$18.00
Low target$10.00
Implied upside60.83%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders12.83%
Held by institutions69.64%
Institutions holding152
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.42M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 9, 26 | SPANGLER PATRICK D Director |
STOCK | 34.52K | $0 | Direct |
| Jun 9, 26 | KLEMA CATHERINE M Director |
STOCK | 34.52K | $0 | Direct |
| Jun 9, 26 | WASSON GREGORY D Director |
STOCK | 34.52K | $0 | Direct |
| Jun 9, 26 | VOS ELLEN O CONNOR Director |
STOCK | 34.52K | $0 | Direct |
| Jun 9, 26 | LANG JAMES PAUL Director |
STOCK | 34.52K | $0 | Direct |
| Jun 9, 26 | VARGHESE PRESTI MARY VARGHESE Director |
STOCK | 17.26K | $0 | Direct |
| May 1, 26 | VARGHESE PRESTI MARY VARGHESE Director |
STOCK | 13.06K | $0 | Direct |
| Feb 11, 26 | ODENCE-FORD MARION K. Officer |
— | 4.00K | — | Direct |
| Dec 19, 25 | STELMAKH EDWARD Chief Financial Officer |
SELL | 1.39K | $18.75K | Direct |
| Dec 19, 25 | SILVESTRO STEPHEN L Chief Executive Officer |
— | 6.55K | — | Direct |
| Dec 19, 25 | ODENCE-FORD MARION K. Officer |
— | 3.93K | — | Direct |
| Dec 19, 25 | STELMAKH EDWARD Chief Financial Officer |
— | 5.24K | — | Direct |
| Dec 19, 25 | STELMAKH EDWARD Chief Financial Officer |
— | 5.24K | — | Direct |
| Dec 19, 25 | BESCH DOUG Chief Technology Officer |
— | 1.96K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BESCH DOUG |
Chief Technology Officer | 70.95K | Conversion of Exercise of derivative security |
FEBBO WILLIAM J |
Chief Executive Officer | 601.25K | Purchase |
GRECO THERESA |
Officer | 75.98K | Stock Award(Grant) |
LANG JAMES PAUL |
Director | 433.84K | Stock Award(Grant) |
ODENCE-FORD MARION K. |
Officer | 91.94K | Conversion of Exercise of derivative security |
SILVESTRO STEPHEN L |
Chief Executive Officer | 193.87K | Conversion of Exercise of derivative security |
SPANGLER PATRICK D |
Director | 78.73K | Stock Award(Grant) |
STELMAKH EDWARD |
Chief Financial Officer | 126.83K | Sale |
VOS ELLEN O CONNOR |
Director | 107.16K | Stock Award(Grant) |
WASSON GREGORY D |
Director | 91.70K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
7.87
-2.05% from price
SMA 20
7.21
+6.88% from price
SMA 50
6.39
+20.67% from price
SMA 100
6.16
+25.20% from price
SMA 200
8.78
-12.17% from price
EMA 12
7.71
-0.05% from price
EMA 26
7.21
+6.94% from price
EMA 50
6.77
+13.95% from price
RSI (14)
58.3
Neutral
MACD (12,26,9)
0.50
Hist 0.04
ATR (14)
0.61
7.91% of price
Realised vol 30D
77.2%
Annualised
Bollinger upper
8.91
20, 2σ
Bollinger lower
5.52
20, 2σ
50 / 200 cross
Death
6.39 vs 8.78
Trend bias
Below 200
-12.17%
Risk profile
Beta vs SPY
2.07
More volatile than market
Correlation to SPY
0.36
Loosely linked
Realised vol 30D
77.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-79.1%
Peak to trough
Max drawdown 5Y
-96.1%
Peak to trough
ATR 14
0.61
7.91% of price
Beta (reported)
1.05
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.51
Put-heavy session
Put / call open interest
0.33
Positioning, not flow
Max pain
5.00
-35.1% from spot
ATM implied vol
112.5%
Nearest strike to spot
Skew (10% OTM)
-44.1%
Calls bid over puts
Call volume
271
Contracts, this expiry
Put volume
409
Contracts, this expiry
Heaviest call OI
10.00
656 contracts
Heaviest put OI
7.50
353 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript
Motley Fool · 3d ago
OptimizeRx Corporation Q2 2026 Earnings Call Summary
Moby · 9d ago
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ...
GuruFocus.com · 10d ago
OptimizeRx Q2 Earnings Call Highlights
MarketBeat · 10d ago
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
Zacks · 10d ago
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
GlobeNewswire · 10d ago
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
GlobeNewswire · 10d ago
Earnings To Watch: OptimizeRx Corp (OPRX) Q2 2026 -- GF Value Sees 106% Upside
GuruFocus.com · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.